Trial Profile
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 01 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 03 Mar 2022 The trial has been completed in Spain, according to European Clinical Trials Database record
- 17 Jan 2022 Status changed from recruiting to active, no longer recruiting.